Metri Bio's CEO, Ashley Abel, selected for Forbes 30 Under 30
Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics

Michele Keough Joins Metri Bio as Chief Operating Officer

Metri Bio has appointed Michele Keough as Chief Operating Officer, bringing more than two decades of experience building and scaling biotechnology organizations. Across leadership roles in research strategy, operations, and alliance management, Michele has helped guide complex therapeutic programs from early development through organizational growth. Most recently, Michele served in senior leadership roles at Moderna, […]

Metri Bio Expands Its Voice Across Women’s Health and Biotechnology

The Metri team at the Women’s Health Summit Throughout the second quarter of 2026, Metri Bio contributed to conversations shaping the future of biotechnology, women’s health, and endometriosis research. CEO and co-founder Ashley Abel represented the company at major industry gatherings, including the Forbes 30 Under 30 Summit, the Yale Innovation Summit, MIT’s Science and […]

Dr. Michael Rogers Joins Metri Bio’s Scientific Advisory Board

Metri Bio has welcomed Michael S. Rogers, PhD, to its Scientific Advisory Board. Dr. Rogers is an Associate Professor of Surgery at Harvard Medical School and a principal investigator in the Vascular Biology Program at Boston Children’s Hospital, where his laboratory develops new approaches to understand and treat endometriosis-associated pain. Dr. Rogers and his collaborators […]

Metri Bio Featured in EndoRISE’s “1 in 10” Endometriosis Story

The Jackson Laboratory’s feature on EndoRISE highlights Connecticut’s first-in-the-nation, state-supported effort to accelerate endometriosis research, care, education, and awareness. Metri Bio co-founder Ashley Abel appears in the story alongside researchers, patients, advocates, and public leaders working to create a more coordinated model for progress, emphasizing the need for a quantum leap in endometriosis research rather […]

Pillar VC Shares Why It Invested in Metri Bio

In “Immovable Object, Meet Unstoppable Force,” Pillar VC’s Thomas de Vlaam reflects on the scientific complexity of endometriosis, the scale of its unmet need, and the convergence of people and technology behind Metri Bio. The article traces Ashley Abel’s path from Yale research to building a company focused on human-relevant models and the discovery of […]

Metri Bio CEO Ashley Abel Selected for the 2026 Termeer Fellowship

Metri Bio CEO and co-founder Ashley Abel has been selected for the 2026 Termeer Fellowship, a highly competitive leadership program for emerging life sciences CEOs. Through mentorship, peer learning, and access to an experienced network of biotechnology leaders, the fellowship supports founders as they scale companies working to address major unmet needs in healthcare. Ashley […]

HealthyWomen Profiles Ashley Abel’s Mission to End Endometriosis

HealthyWomen spoke with Metri Bio CEO and co-founder Ashley Abel about the scientific insight that inspired the company, the limitations of existing endometriosis models, and Metri’s work to build patient-derived human tissue models for discovering targeted therapies. The conversation also explores why endometriosis should be understood as a full-body disease, not only a fertility condition, […]

Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics​

Metri Bio has raised $5 million in an oversubscribed pre-seed financing round led by Pillar VC, with participation from Pace Ventures, Slocum Management, Navec Investments, and angel investors. The Boston-based biotechnology company is developing therapies for endometrial diseases. The Boston-based company emerged from stealth with the funding announcement. Metri Bio was co-founded by Berna Sozen, […]